Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

"ArkBio commences Phase II study of AK0610 for RSV prevention" was originally created and published by Clinical Trials Arena, ...

A shareholder class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX). The lawsuit alleges that Defendants made ...

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery ...

Achieved commercially viable yield for IM1240, positioning the program competitively for future developmentValidates ...

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com .

Nitazenes, a class of synthetic drugs 40 times more potent than fentanyl, are steadily becoming more common on both sides of ...

Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.